SSAs stimulate p27 expression and inhibit the MAPK pathway in pituitary tumors by binding to SSRT2 and SSRT5 [17–19].Studies have found that SSTR2 and SSTR5 also express in TSHoma cells, suggesting that SSAs can be used to treat TSHoma [8, 9]. Here, SSTR5 is linked to TSH-secreting pituitary adenoma.